On the basis of the results in Fig. 3d–i, we found that addition of a SRC inhibitor to a BRAF inhibitor had an equivalent or better effect on tumor growth inhibition in comparison to adding an EGFR inhibitor to a BRAF inhibitor. Here, SRC is linked to neoplasm.